

Hereditary Hemorrhagic Telangiectasia

Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant genetic disorder that leads to abnormal blood vessel formation in the skin, mucous membranes, and often in organs such as the lungs, liver, and brain. Genetic testing can confirm a diagnosis.

DISEASE OVERVIEW

Symptoms

- Spontaneous and recurring nosebleeds
- Cutaneous and/or mucosal telangiectases, predominantly on the face, lips, hands, and in oral, nasal, and gastrointestinal mucosa
- Arteriovenous malformations (AVMs) affecting the lungs, liver, and brain
- HHT symptoms and juvenile polyps are present with juvenile polyposis syndrome (JPS)/HHT (*SMAD4*)

Penetrance

- Approximately 95% of individuals will develop nosebleeds or telangiectases.
- Penetrance is age dependent.

Prevalence

1/10,000

Inheritance

Autosomal dominant

TEST DESCRIPTION

See the [Genes Tested](#) table for the coding regions and intron-exon boundaries of six genes, the 5' untranslated region of *ENG*, and a region of *ACVRL1* intron 9 encompassing the CT-rich variant hotspot region.

Clinical sensitivity

- 87% of individuals meeting consensus clinical diagnostic criteria for HHT will have a causative variant in one of the genes tested.
 - Variable for those with symptoms but who do not meet diagnostic criteria
- *ACVRL1* and *ENG* are causative for ~85% of HHT (Bossler, 2006; Gedge, 2007; Prigoda, 2006; Richards Yutz, 2010).
 - 75% detectable by sequencing
 - 10% detectable by large deletion/duplication analysis
- *SMAD4* is causative for 1-3% of HHT (Prigoda, 2006)
- *BMP9/GDF2* mutation are detected in <1% of individuals with no other causative variants (Wooderchak-Donahue, 2013).
- The clinical sensitivity for *EPHB4* is unknown.

Limitations

TESTS TO CONSIDER

[Hereditary Hemorrhagic Telangiectasia \(HHT\) Panel, Sequencing and Deletion/Duplication 2009337](#)

Method: Massively Parallel Sequencing/Exonic Oligonucleotide-based CGH Microarray

Recommended test for symptomatic individuals who do not meet clinical criteria for HHT

[Hereditary Hemorrhagic Telangiectasia \(ACVRL1 and ENG\) Sequencing and Deletion/Duplication 0051382](#)

Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

Recommended test for symptomatic individuals who meet clinical criteria for HHT

[Hereditary Hemorrhagic Telangiectasia \(ACVRL1 and ENG\) Sequencing and Deletion/Duplication with Reflex to Juvenile Polyposis \(SMAD4\) Sequencing and Deletion/Duplication 2009008](#)

Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

Recommended test for symptomatic individuals who meet clinical criteria for HHT

[Hereditary Hemorrhagic Telangiectasia \(ACVRL1 and ENG\) Sequencing 0051381](#)

Method: Polymerase Chain Reaction/Sequencing

[Familial Mutation, Targeted Sequencing 2001961](#)

Method: Polymerase Chain Reaction/Sequencing

- Recommended test for a known familial sequence variant previously identified in a family member.

- A negative result does not exclude a diagnosis of HHT or overlapping disorders.
- Diagnostic errors can occur due to rare sequence variations.
- Interpretation of this test result may be impacted if the individual has had an allogeneic stem cell transplantation.
- The following will not be evaluated:
 - Variants outside the coding regions and intron-exon boundaries of the targeted genes
 - Regulatory region variants and deep intronic variants
 - Breakpoints of large deletions/duplications
 - Deletions/duplications in *EPHB4*
- The following may not be detected:
 - Deletions/duplications/insertions of any size by massively parallel sequencing
 - Deletions/duplications less than 1kb in the targeted genes by array
 - Some variants due to technical limitations in the presence of pseudogenes, repetitive, or homologous regions
 - Low-level somatic variants

- A copy of the family member's test results documenting the known familial variant is required.

See [Related Tests](#)

Analytical Sensitivity

For massively parallel sequencing:

Variant Class	Analytical Sensitivity (PPA) Estimate ^a (%)	Analytical Sensitivity (PPA) 95% Credibility Region ^a (%)
SNVs	99.2	96.9-99.4
Deletions 1-10 bp	93.8	84.3-98.2
Deletions 11-44 bp	100	87.8-100
Insertions 1-10 bp	94.8	86.8-98.5
Insertions 11-23 bp	100	62.1-100

^a Genes included on this test are a subset of a larger methods-based validation from which the PPA values are derived. bp, base pairs; PPA, positive percent agreement; SNVs, single nucleotide variants

Genes Tested

Gene	Alias Symbol(s)	MIM Number	Disorder
ACVRL1	ACVRLK1, ORW2, HHT2, ALK1, HHT	601284	HHT, type 2
ENG	ORW1, ORW, END, HHT1, CD105	131195	HHT, type 1
EPHB4	HTK, Tyro11	600011	CM-AVM
GDF2	BMP-9, BMP9	605120	HHT, type 5
RASA1	RASA, GAP, CM-AVM, p120GAP, p120RASGAP, p120	139150	CM-AVM, Parkes Weber syndrome
SMAD4	MADH4, DPC4	600993	JPS, JPS/HHT

CM-AVM, capillary malformation-arteriovenous malformation

REFERENCES

Amyere M, Revencu N, Helaers R, Pairet E, Baselga E, Cordisco M, Chung W, Dubois J, Lacour J, Martorell L, Mazereeuw-Hautier J, Pyeritz RE, Amor DJ, Bisdorff A, Blei F, Bombei H, Domp Martin A, Brooks D, Dupont J, González-Enseñat MA, Frieden I, Gérard M, Kvarnung M, Hanson-Kahn AK, Hudgins L, Léauté-Labrèze C, McCuaig C, Metry D, Parent P, Paul C, Petit F, Phan A, Quere I, Salhi A, Turner A, Vabres P, Vicente A, Wargon O, Watanabe S, Weibel L, Wilson A, Willing M, Mulliken JB, Boon LM, Vikkula M. [Germline Loss-of-Function Mutations in EPHB4 Cause a Second Form of Capillary Malformation-Arteriovenous Malformation \(CM-AVM2\) Deregulating RAS-MAPK Signaling](#). *Circulation*. 2017; 136(11): 1037-1048. PubMed

Bossler AD, Richards J, George C, Godmilow L, Ganguly A. [Novel mutations in ENG and ACVRL1 identified in a series of 200 individuals undergoing clinical genetic testing for hereditary hemorrhagic telangiectasia \(HHT\): correlation of genotype with phenotype](#) *Hum Mutat*. 2006; 27(7): 667-75. PubMed

Faughnan ME, Palda VA, Garcia-Tsao G, Geisthoff UW, McDonald J, Proctor DD, Spears J, Brown DH, Buscarini E, Chesnutt MS, Cottin V, Ganguly A, Gossage JR, Guttmacher AE, Hyland RH, Kennedy SJ, Korzenik J, Mager JJ, Ozanne AP, Piccirillo JF, Picus D, Plauchu H, Porteous ME, Pyeritz RE, Ross DA, Sabba C, Swanson K, Terry P, Wallace MC, Westermann CJ, White RI, Young LH, Zarrabeitia R, HHT Foundation International - Guidelines Working Group. [International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia](#). J Med Genet. 2011; 48(2): 73-87. PubMed

Gedge F, McDonald J, Phansalkar A, Chou L, Calderon F, Mao R, Lyon E, Bayrak-Toydemir P. [Clinical and analytical sensitivities in hereditary hemorrhagic telangiectasia testing and a report of de novo mutations](#) J Mol Diagn. 2007; 9(2): 258-65. PubMed

Marchuk DA, Guttmacher AE, Penner JA, Ganguly P. [Report on the workshop on Hereditary Hemorrhagic Telangiectasia, July 10-11, 1997](#). Am J Med Genet. 1998; 76(3): 269-73. PubMed

Porteous ME, Burn J, Proctor SJ. [Hereditary haemorrhagic telangiectasia: a clinical analysis](#). J Med Genet. 1992; 29(8): 527-30. PubMed

Prigoda NL, Savas S, Abdalla SA, Piovesan B, Rushlow D, Vandezande K, Zhang E, Ozcelik H, Gallie BL, Letarte M. [Hereditary haemorrhagic telangiectasia: mutation detection, test sensitivity and novel mutations](#) J Med Genet. 2006; 43(9): 722-8. PubMed

Richards-Yutz J, Grant K, Chao EC, Walther SE, Ganguly A. [Update on molecular diagnosis of hereditary hemorrhagic telangiectasia](#) Hum Genet. 2010; 128(1): 61-77. PubMed

Wooderchak-Donahue WL, McDonald J, O'Fallon B, Upton PD, Li W, Roman BL, Young S, Plant P, Fülöp GT, Langa C, Morrell NW, Botella LM, Bernabeu C, Stevenson DA, Runo JR, Bayrak-Toydemir P. [BMP9 mutations cause a vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia](#). Am J Hum Genet. 2013; 93(3): 530-7. PubMed

RELATED INFORMATION

[Hereditary Hemorrhagic Telangiectasia - HHT](#)

RELATED TESTS

[Juvenile Polyposis \(SMAD4\) Sequencing and Deletion/Duplication 2001971](#)

Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

[Telangiectasia Syndrome \(BMP9/GDF2\) Sequencing 2010015](#)

Method: Polymerase Chain Reaction/Sequencing

[RASA1-Related Disorders \(RASA1\) Sequencing and Deletion/Duplication 2007852](#)

Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

[Capillary Malformation-Arteriovenous Malformation \(EPHB4 and RASA1\) Sequencing, and \(RASA1\) Deletion/Duplication 3001132](#)

Method: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification

[Capillary Malformation-Arteriovenous Malformation 2 \(EPHB4\) Sequencing 3001129](#)

Method: Polymerase Chain Reaction/Sequencing

ARUP Laboratories is a nonprofit enterprise of the University of Utah and its Department of Pathology.
500 Chipeta Way, Salt Lake City, UT 84108 | (800) 522-2787 | (801) 583-2787 | [aruplab.com](#) | [arupconsult.com](#)
Content Review November 2018 | Last Update February 2019

© 2019 ARUP Laboratories. All Rights Reserved.